WO1998001166A1 - Traitement de blessures - Google Patents
Traitement de blessures Download PDFInfo
- Publication number
- WO1998001166A1 WO1998001166A1 PCT/GB1997/001813 GB9701813W WO9801166A1 WO 1998001166 A1 WO1998001166 A1 WO 1998001166A1 GB 9701813 W GB9701813 W GB 9701813W WO 9801166 A1 WO9801166 A1 WO 9801166A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- kit
- wound
- film
- gel
- agent
- Prior art date
Links
- 206010052428 Wound Diseases 0.000 title claims abstract description 34
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 34
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 17
- 208000015181 infectious disease Diseases 0.000 claims abstract description 15
- 201000009030 Carcinoma Diseases 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000007788 liquid Substances 0.000 claims abstract description 8
- 230000001788 irregular Effects 0.000 claims abstract description 5
- 230000001684 chronic effect Effects 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 12
- 210000000416 exudates and transudate Anatomy 0.000 claims description 7
- 239000012530 fluid Substances 0.000 claims description 7
- 229920000615 alginic acid Polymers 0.000 claims description 5
- 235000010443 alginic acid Nutrition 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 4
- 230000002745 absorbent Effects 0.000 claims description 4
- 239000002250 absorbent Substances 0.000 claims description 4
- 229940072056 alginate Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 238000011065 in-situ storage Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 210000002268 wool Anatomy 0.000 claims description 2
- 238000001804 debridement Methods 0.000 claims 1
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 206010056340 Diabetic ulcer Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010068834 Fungating wound Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/023—Adhesive bandages or dressings wound covering film layers without a fluid retention layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/38—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L2300/254—Enzymes, proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
Definitions
- the present invention relates to the treatment of chronic wounds of an irregular 3D nature.
- the invention relates more particularly (but not exclusively) to the treatment of fungating carcinomas, i.e. cancers that erupt tluough the skin causing a continuous breakdown of surface tissues either by cancerous undermining or excess exudate levels eroding the periphery. All of these wounds are heavily colonised, predisposed to infections and malodorous. The wounds degrade the life of both the patient and the carer.
- kits for the treatment of irregular 3D wounds comprising a breathable film which is of increased MVTR capability in the presence of liquid water as compared to moisture vapour only, and an agent for infection control.
- the agent for infection control serves not only to control infection but also limit odour.
- wounds to which the kit of the present invention is applicable include fungating carcinomas and diabetic ulcers.
- the breathable film is preformed so as to be contoured to the portion of the body and/or the shape of the wound to which the dressing is to be applied.
- contoured dressings may be formed, for example, by a dipping process using a former corresponding to the desired "shape" of the dressing and provide a convenient way of dressing an irregular 3D wound.
- contoured dressings include two apertures (e.g. upper and lower apertures) such that exudate may be drained from one aperture and treatment agents introduced to the wound through the other aperture.
- Exudate drainage may be by means of a tube attached to the film.
- the tube may drain into a bag or the like.
- a collar, flange or the like e./g. a (lal annular ring) located around the drainage aperture for the purpose of mounting the tube in position.
- the bag may be mounted directly onto the film such that exudate passes through the aperture directly into the bag.
- treatment agents which may be introduced through the other aperture (which may also be surrounded by a collar, flange or the like) include further infection control agent or iodine to clean the wound.
- kit of the invention may include
- the components (i)-(iii) may be used for filling or packing the wound so as to provide a more regular "structure" to which a flat breathable film may be applied. It is however also possible to incorporate one or more of components (i) to (iii) in a kit incorporating a pre-contoured film dressing.
- Examples of (i) include absorbent fibrous materials such as alginates in any of a variety of formats, e.g. ropes, felt or wool.
- Preferred examples of (I) comprise alginate fibres co-spun with at least one other polysaccharide as disclosed in WO-A- 96/10106 (Innovative Technologies).
- a particular example of (ii) is an alginate gel.
- Preferred examples of (ii) are compositions as disclosed in WO-A-96/13285 (Innovative Technologies) and our copending U.K. Patent Application No. 9609474.
- examples of (iii) include foams and gels.
- kit may incorporate a polysaccharide which may be applied as a spray (e.g. from an aerosol) to fill the wound.
- a polysaccharide which may be applied as a spray (e.g. from an aerosol) to fill the wound.
- the purpose of the film is lo cover the wound and block out odour.
- the film also vents fluid from the wound, protects clothing from wound fluid and prevents ingress of dirt, bacteria and other micro-organisms into the wound.
- the film may be provided with an adhesive (e.g. a patterned adhesive) which allows passage of moisture vapour tlirough the adhesive layer.
- an adhesive e.g. a patterned adhesive
- a relatively thick layer of adhesive may be required around the periphery of films to be used as dressings for fungating carcinomas in view of the very high levels of exudate.
- the film is a breathable film which is increased MVTR capability in the presence of liquid water as compared to moisture vapour only.
- MVTR in the presence of liquid water may be measured by ASTM E96BW whereas MVTR in the presence of moisture vapour alone may be measured by ASTM E96B (water method).
- ASTM E96BW water method
- the value of the breathability in the presence of liquid water is at least twice and preferably at least three times that in the presence of moisture vapour alone. The value may be up to 30 or 40 times that for moisture vapour alone.
- the film will be of a material which has an MVTR in the presence of moisture vapour alone (ASTM E96B) of 2,000 to 2,500 g m "2 24hr ' ' and an MVTR in the presence of liquid water (ASTM E96BW) in the range 6,000 to 30,000 g m '2 24hr " ' (e.g. 600 to 10,000 g m "2 24hr " ').
- the film will have a thickness of 30-70 microns more preferably 40-60 microns, e.g. about 50 microns.
- the film may for example be of polyurethane. Suitable films are available from Alternative Technologies Limited under the designations B532. C542 and D562.
- the agent for infection control comprises a solution or paste of a non-reducing sugar and iodine in a vehicle consisting essentially of a pharmacologically acceptable glycol and. optionally, water.
- a composition is disclosed in WO-A-94/1781 1 ( cConn-Stern) and is referred to herein as a composition of the kind defined.
- the principal use of the composition of the kind defined as disclosed in WO-A-94/1781 1 is in veterinary medicine, particularly the treatment of mastitis.
- Other applications disclosed in WO-A-94/1781 1 include treatment of deep varicose vein ulcers, burns, and decubitus ulcers in human patients. All compositions disclosed in WO-A-94/1781 1 may be used in the present invention.
- the agent for infection control may be a debride ent enzyme such as PHM-101 (ex Phairson Ltd.).
- the infection control agenl may, for example, be provided in the form of an ointment, e.g. in a table. However, irrespective of its exact chemical formulation or physical form the agent is applied to the exposed surfaces ofthe wound.
- the kit in accordance with the invention may be used, for example, for the treatment of diabetic ulcers but is particularly suitable for treatment of fungating carcinomas for which purpose it is particularly preferred that the agent for infection control is a composition of the kind defined.
- the composition controls the infections and foul odour associated with fungating carcinomas without being toxic. Therefore according to a second aspect of the present invention there is provided the use of the composition of the kind defined for the manufacture of a medicament for the treatment of fungating carcinomas.
- kits allow treatment to be tailored to the requirements of a particular patient and are substantially cheaper than conventionally used dressings which cost about £ 10- 100/patients/day and are not entirely effective.
- the reason why the prior art dressings are not effective is that they tend to be flat rectangular sheets that do not have the conformability to fit the 3D structures of the fungating wound or the site, and leakage occurs around the edge. Disadvantages are overcome by the kits of the present invention.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU36266/97A AU3626697A (en) | 1996-07-04 | 1997-07-04 | Treatment of wounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9614034.8A GB9614034D0 (en) | 1996-07-04 | 1996-07-04 | Treatment of wounds |
GB9614034.8 | 1996-07-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998001166A1 true WO1998001166A1 (fr) | 1998-01-15 |
Family
ID=10796343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1997/001813 WO1998001166A1 (fr) | 1996-07-04 | 1997-07-04 | Traitement de blessures |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU3626697A (fr) |
GB (1) | GB9614034D0 (fr) |
WO (1) | WO1998001166A1 (fr) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0541251A1 (fr) * | 1991-11-01 | 1993-05-12 | Ferris Mfg., Corp. | Pansement flexible |
WO1996008223A1 (fr) * | 1994-09-13 | 1996-03-21 | Polymedica Industries, Inc. | Pansements spirosorbants avec capacite de regulation des exsudats |
WO1996013282A1 (fr) * | 1994-10-27 | 1996-05-09 | Innovative Technologies Limited | Pansement |
WO1996022753A1 (fr) * | 1995-01-26 | 1996-08-01 | Innovative Technologies Limited | Pansement pour blessures |
WO1997011658A1 (fr) * | 1995-09-26 | 1997-04-03 | Smith & Nephew Plc | Pansement absorbant pouvant epouser diverses formes |
-
1996
- 1996-07-04 GB GBGB9614034.8A patent/GB9614034D0/en active Pending
-
1997
- 1997-07-04 AU AU36266/97A patent/AU3626697A/en not_active Abandoned
- 1997-07-04 WO PCT/GB1997/001813 patent/WO1998001166A1/fr active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0541251A1 (fr) * | 1991-11-01 | 1993-05-12 | Ferris Mfg., Corp. | Pansement flexible |
WO1996008223A1 (fr) * | 1994-09-13 | 1996-03-21 | Polymedica Industries, Inc. | Pansements spirosorbants avec capacite de regulation des exsudats |
WO1996013282A1 (fr) * | 1994-10-27 | 1996-05-09 | Innovative Technologies Limited | Pansement |
WO1996022753A1 (fr) * | 1995-01-26 | 1996-08-01 | Innovative Technologies Limited | Pansement pour blessures |
WO1997011658A1 (fr) * | 1995-09-26 | 1997-04-03 | Smith & Nephew Plc | Pansement absorbant pouvant epouser diverses formes |
Also Published As
Publication number | Publication date |
---|---|
GB9614034D0 (en) | 1996-09-04 |
AU3626697A (en) | 1998-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0788378B2 (fr) | Pansement | |
EP0805662B1 (fr) | Pansement pour blessures | |
US7619130B2 (en) | Multi-layer wound dressing formed as a single unit | |
JP4383652B2 (ja) | 創傷包帯剤 | |
AU2002365308B2 (en) | Absorbent wound dressing containing a hydrogel layer | |
AU601471B2 (en) | Wound dressing, its preparation and use | |
US8158845B2 (en) | Wound dressing | |
US20100262090A1 (en) | Wound care article for extraction and control of wound fluids | |
WO2018226592A1 (fr) | Pansement pour plaie avec absorption d'odeurs et transmission accrue de vapeur d'humidité | |
CA2081789A1 (fr) | Pansement souple | |
MXPA00000865A (es) | Vendaje para heridas mejor | |
WO2003043553A1 (fr) | Pansement | |
CA2254904A1 (fr) | Pansement pour blessure avec joint etanche empechant les fuites | |
US20060211972A1 (en) | Wound dressing | |
EP1333788A1 (fr) | Pansements avec couche d'hydrogels | |
CN101272752A (zh) | 具有斜边的泡沫 | |
Thomas | A structured approach to the selection of dressings | |
EP0106439A1 (fr) | Pansement et sa fabrication | |
EP1601388B1 (fr) | Materiaux hydrocolloides destines a etre utilises dans la cicatrisation des blessures | |
WO1998001166A1 (fr) | Traitement de blessures | |
Turner | Interactive dressings used in the management of human soft tissue injuries and their potential in veterinary practice | |
CN2311268Y (zh) | 医用复合活性炭纤维毡敷料 | |
EP1653899B1 (fr) | Feuille absorbante anti-fuites pour pansement | |
Auböck | Synthetic dressings | |
Degreef et al. | Dressings as a new concept for topical treatment of ulcers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 98504927 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |